Treatment of Wegener's Granulomatosis With Cyclophosphamide
Completed · Phase 2
Conditions studied: Vasculitis, Wegener's Granulomatosis
In brief
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Key facts
- Study ID
- NCT00001155
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 200
- Starts
- 1976-02-01
- Expected to finish
- 2002-02-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Institute of Allergy and Infectious Diseases (NIAID) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.